Study Levels of Some Biochemical Parameters in Serum of Pancreatic Cancer Patients
Article Sidebar
Main Article Content
Abstract
This study included an estimation for the levels of some biochemical parameters in the serum of those pancreatic cancer patients, by collecting (40) blood samples from patients their ages ranged (30-70) years compared with (55) blood samples of healthy persons as control group. The parameters included Super oxide dismutase, Amylase, Ribonuclease (acidic and alkaline), Arylesterase, Alkaline phosphatease, Carcinoembryonic antigen, carbohydrate antigen 19-9, Total lipid and Bilirubin Results of the Statistical analysis indicated a significant decrease in the activity of Amylase and Super oxide dismutase patients in comparison with the control group. There was a significant increase in the activity of Ribonuclease (acidic and alkaline), Arylesterase, Alkaline phosphatease, Carcinoembryonic antigen, carbohydrate antigen 19-9, Total lipid and Bilirubin in patients in comparison with the control group.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Tikrit Journal of Pure Science is licensed under the Creative Commons Attribution 4.0 International License, which allows users to copy, create extracts, abstracts, and new works from the article, alter and revise the article, and make commercial use of the article (including reuse and/or resale of the article by commercial entities), provided the user gives appropriate credit (with a link to the formal publication through the relevant DOI), provides a link to the license, indicates if changes were made, and the licensor is not represented as endorsing the use made of the work. The authors hold the copyright for their published work on the Tikrit J. Pure Sci. website, while Tikrit J. Pure Sci. is responsible for appreciate citation of their work, which is released under CC-BY-4.0, enabling the unrestricted use, distribution, and reproduction of an article in any medium, provided that the original work is properly cited.
References
[1] American Cancer Society. (2014). Genes and Cancer.
[2] Ana, U. (2013), Pancreatic Cancer. European Society for Medical Oncology, (1).
[3] Ali, S. (2016). Hop for the further: Tackling inequalities in Pancreatic cancer care.
[4] Hannah, F. et. al. (2016). The Prognostic Lmpact of the Carcino embryonic Antigen in Ampullary Cancer–A Retrospective Single Center Study. Journal of Cancer, l.8(4):657-664.
[5] Barkha, S.; Ankita, M. and Shubham, S.; (2016) Role of Probiotics in Pancreatic Cancer Prevention: The Prospects and Challenges. Advances in Bioscience and Biotechnology, (7):468-500.
[6] Maureen, M. (2012). pancreatic cancer and diabetes. chapter 18. Landes Bioscience and springer.
[7] Whiteman, D.C. et al. (2015). cancers in Australia in 2010 attributable to modifiable factor: introduction and overview. Aust. N.Z.J. public Hearth, (39):403-407.
[8] Pancreatic, C. UK. (2016). Signs and symptoms of pancreatic cancer. Support @ pancreatic cancer org.UK.
[9] American Cancer Society, (2014). Cancer Facts and Figures. Atlanta.
[10] Tietz, N.W. (1999). Text book of clinical chemistry. W.B. Saunders company, Philadelphia: 490–491, 1000–1025, 1245–1250.
[11] Beyer, W.; Mlay, J. and Fridovich, I. (1991). Supperoxide dismutase. Prog nuclic acid Res. Mol. Biol., (40):221- 253.
[12] Tomas, M. et. al. (2000). Effect of simvastatin therapy on paraoxonase activity and related lipoprotein in familial hypercholestrolemic patients. Arteriosclar. Thromb. Vasc. Biol., (20):2113.
[13] Bardon, A. and Shugar, D. (1980). Properties of Purified Salivary Ribonuclease and Salivary Ribonuclease levels in children with cystic fibrosis and in heterozygous Carriers. Clin. Chem. Acta. Feb., 14 :101(1):17-24.
[14] Bardon, A.; Ceder, O. and Kollberg, H. (1983). Cystic fibrosis-like change in saliva of healthy persons subjected to anaerobic exercise. Clin. Chem. Acta., (133):311-316.
[15] Kind, P.R.N. and King, E.J. (1954). Estimation of plasma phosphatease by determination of hydrolyzed phenol with amino – antipyrine. Journal Clin. Path., (7):322-326.
[16] Magnani, J.; Steplewski, Z.; Koprowski, H. and Ginsburg, V. (1983) Identification of the Gastrointestinal and pancreatic cancer–Associated Antigen Detected by Monoclonal Antibody 19-9 in the sera of Patients as a Mucin. Cancer Res., (43):5489.
[17] Chabrol, and Chardonnet, (1937). Cited by Gelson Toro and Philip G. Ackermanin (1975), practical clinical chemistry. Little, Brown and Company Boston.
[18] Malloy, H.T. and Evelyn, K. (1937). Journal Biol. Chem., (119): 481-490.
[19] Walters, M. and Gerarde, H. (1970). Micro chem. Journal, (15):231-243.
[20] Andrea, C.G. et. al. (2016). paraneoplastic Lipase and amylase production in a patient with small–cell lung cancer: case report. BMC cancer (16):118.
[21] Cullen, J.J. et. al. (2003). the role of manganese superoxide dismutase in the growth of pancreatic adenocarcinoma. cancer Res., (63):1297-303.
[22] Justin, G.W.; Matthew, S.A, and Joseph, J.G. (2017). Superoxide Dismutases in pancreatic cancer. Journal antioxidants., 6,66, doi: (10):3390.
[23] Ferre, N. et. al. (2003). Regulation of paraoxonase activity by genetic nutritionak and life style factors in general population. Clin. Chem., (49):1491-1497.
[24] Reddi, K.K. and Holland, J.F. (1976). Elevated serum Ribonuclease in patients with pancreatic cancer. proc. Natl. Acad. Sci. USA., (73):2308-10.
[25] Joachim, L.W.; Erik M.O. and Dohn G.G. (1984). Immunological Assay of Pancreatic Ribonuclease in Serum as an Indicator of pancreatic cancer. Cancer Research., l (44):1682-1687.
[26] Giuseppe, B. et. al. (1993). Behavior of tumer marker CA19-9, CA195, CAM43, CA242 and TPS in the diagnosis and follow–VP of pancreatic cancer. Clin. Chem., 39 (3):420-423.
[27] Xaoli, J. and Yulain W.U. (2015). Diagnostic Utility of clinical and biochemical parameters in pancreatic head malignancy patients with normal carbohydrate antigen 19-9 levels. African Health Sciences., 15 (1).